Physician profile
Monica Benavidez
NPI 1710182225
$434,728.67
in general payments reported to CMS, 2019-2025
13 companies · $255K in 2025
The $255K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,986 · 2020: $867 · 2021: $2,273 · 2022: $2,716 · 2023: $58K · 2024: $114K · 2025: $255K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $318K · Travel and Lodging: $72K · Food and Beverage: $20K · Consulting Fee: $17K · Education: $96.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $318,044.00 |
| Travel and Lodging | $72,238.67 |
| Food and Beverage | $19,913.17 |
| Consulting Fee | $16,594.00 |
| Education | $96.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $239,775.47 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $95,084.41 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $91,701.38 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $2,185.15 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $1,523.43 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,501.73 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,254.73 | 2021-2025 | Caplyta |
| Indivior INC. | $585.65 | 2019-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $384.03 | 2019-2022 | |
| Abbvie INC. | $370.29 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $331.43 | 2019-2025 | Fanapt |
| Servier Pharmaceuticals LLC | $18.60 | 2024 | |
| Allergan, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Benavidez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.